Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
International journal of molecular sciences · 2025
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 4 institutions in 1 country.
Félix Javier Jiménez-JiménezSection of Neurology, Hospital Universitario del Sureste, E28500 Arganda del Rey, Spain.ORCID 0000-0002-7558-7323
Javier Gómez-TabalesARADyAL Instituto de Salud Carlos III, University Institute of Molecular Pathology Biomarkers, Universidad de Extremadura, E10003 Cáceres, Spain.ORCID 0000-0002-8044-1601
Hortensia Alonso-NavarroSection of Neurology, Hospital Universitario del Sureste, E28500 Arganda del Rey, Spain.ORCID 0000-0001-8644-2210
Christopher RodríguezARADyAL Instituto de Salud Carlos III, University Institute of Molecular Pathology Biomarkers, Universidad de Extremadura, E10003 Cáceres, Spain.
Laura Turpín-FenollSection of Neurology, Hospital La Mancha-Centro, E13600 Alcázar de San Juan, Spain.
Jorge Millán-PascualSection of Neurology, Hospital La Mancha-Centro, E13600 Alcázar de San Juan, Spain.
Ignacio ÁlvarezFundació per la Recerca Biomèdica i Social Mútua de Terrassa, E08221 Terrassa, Spain.ORCID 0000-0002-8537-3935
Pau PastorFundació per la Recerca Biomèdica i Social Mútua de Terrassa, E08221 Terrassa, Spain.ORCID 0000-0002-7493-8777
Marisol CallejaSection of Neurology, Hospital Universitario del Sureste, E28500 Arganda del Rey, Spain.
Rafael García-RuizSection of Neurology, Hospital La Mancha-Centro, E13600 Alcázar de San Juan, Spain.
Santiago Navarro-MuñozSection of Neurology, Hospital La Mancha-Centro, E13600 Alcázar de San Juan, Spain.
Marta Recio-BermejoSection of Neurology, Hospital La Mancha-Centro, E13600 Alcázar de San Juan, Spain.
José Francisco Plaza-NietoSection of Neurology, Hospital Universitario del Sureste, E28500 Arganda del Rey, Spain.
Esteban García-AlbeaDepartment of Medicine-Neurology, Universidad de Alcalá, E28801 Alcalá de Henares, Spain.
Elena García-MartínARADyAL Instituto de Salud Carlos III, University Institute of Molecular Pathology Biomarkers, Universidad de Extremadura, E10003 Cáceres, Spain.ORCID 0000-0002-8094-046X
José A G AgúndezARADyAL Instituto de Salud Carlos III, University Institute of Molecular Pathology Biomarkers, Universidad de Extremadura, E10003 Cáceres, Spain.ORCID 0000-0001-6895-9160
Hospital Universitario del Sureste · ESInstituto de Salud Carlos III · ESMútua Terrassa · ESUniversidad de Alcalá · ES
Funding
Instituto de Salud Carlos III PI18/00540Instituto de Salud Carlos III PI21/01683Instituto de Salud Carlos III RETICS RD16/0006/0004 (ARADyAL)Junta de Extremadura, Mérida, Spain GR21073Junta de Extremadura, Mérida, Spain IB20134
6 · The paper itself
Abstract
According to several studies, inflammatory factors could be related to the pathogenesis of idiopathic restless legs syndrome (RLS). In addition, RLS and Parkinson's disease (PD) have shown a possible relationship, and recent studies have shown an association between
Indexed as
CD4 AntigensLymphocyte Activation Gene 3 ProteinParkinson DiseaseRestless Legs SyndromeAllelesGenotypeHumansPolymorphism, Single NucleotideRisk FactorsCD4 AntigensLag3 protein, humanLymphocyte Activation Gene 3 ProteinCD4 genegenetic polymorphismsgeneticsLAG3 generestless legs syndromerisk factors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.